Abstract
Introduction

43
Sarcoidosis is a disease of unknown etiology characterized by granuloma formation involving 44 multiple organ sites 1 . The lungs are the most commonly involved organ; approximately 95% of 45 sarcoidosis patients have computed tomographic (CT) evidence of lung disease 2, 3 . The diagnosis 46 depends on a combination of clinicoradiological features, non-necrotizing granulomas in a tissue 47 biopsy, and exclusion of other etiologies, especially granulomatous infection 4 . Most cases 48 involving the lungs follow a benign course and either resolve spontaneously or respond to steroid 49 treatment; 10 to 30% of patients experience progressive fibrosis resulting in respiratory failure 5- 
51
Little is known about the pathologic features of end stage pulmonary sarcoidosis (ESPS). patients who underwent transplantation for sarcoidosis, dividing their patients into those with 60 "active" and "fibrotic" disease based on the profusion of granulomatous inflammation in the 61 explanted lungs. Patients with "fibrotic" disease included two in whom no granulomas were 62 present. They concluded that late stage fibrotic disease, even when it lacks granulomatous 63 features, is distinct from UIP but they did not include a control group 12 . Tables 1 and   96 2.
97
The control group comprised 10 lung transplant recipients with a pathologic diagnosis of UIP.
98
The underlying clinical condition was IPF in nine, including six men, with a mean age of 54. mean pulmonary artery pressure (mPAP) > 25 mmHg based on right heart catheterization.
112
Histologic findings are summarized in Table 3 . Non-necrotizing granulomas were present in the In contrast, honeycomb change was present in all 10 control UIP cases, involving 5% to 60% of with an alternative diagnosis and those in whom sarcoidosis was combined with another diffuse 188 lung disease.
189
The histologic findings in ESPS are distinctly different from end stage UIP (Table 4 ). The Table 1 . Clinical and radiological information of all cases in the study group. 
